Glenmark Introduces New Polyethylene Glycol 3350 Product to Over-the-Counter Market

Glenmark Therapeutics Unveils Polyethylene Glycol 3350

Glenmark Therapeutics Inc., located in the United States, has officially launched its new product, Polyethylene Glycol 3350 Powder for Solution, designed for over-the-counter use. The product comes in a convenient 17 grams per capful format, intended to fulfill the increasing demand within the market for effective solutions in digestive health. It aims to provide consumers an option comparable to the well-known MiraLAX® brand, recognized widely for its efficacy.

The announcement was made on March 10, 2025, and comes at a time when the market for over-the-counter laxatives is thriving. In the last year alone, the market for MiraLAX® saw impressive sales figures reaching approximately $555.7 million according to Nielsen® data. This positions Glenmark's new offering as a significant competitor in a lucrative industry segment.

Marc Kikuchi, President Business Head of North America at Glenmark, remarked on the launch: "We are excited to introduce our Polyethylene Glycol 3350, fulfilling the growing need for a reliable supplier of high-quality over-the-counter solutions within this category. After high demand for alternatives in the market, we believe our product will address this need effectively." His comments reflect a broader strategy at Glenmark to enhance its product offerings and cater to consumer needs across its therapeutic areas.

This new product underscores Glenmark's dedication to providing high-quality healthcare solutions. The company emphasizes that its Polyethylene Glycol 3350 is marketed strictly for the indications listed in its approved labeling, ensuring compliance with health regulations and safety standards.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals is a globally recognized, research-driven pharmaceutical organization. It focuses on branded, generic, and over-the-counter healthcare products and has established a strong presence in several therapeutic areas, including respiratory conditions, dermatology, and oncology therapies. Their extensive operations span across 80 countries, equipped with 11 world-class manufacturing facilities set up across four continents.

Ranked among the top biopharmaceutical companies, Glenmark's recent reports from Scrip 100 confirm its status in the top tier based on pharmaceutical sales for the year 2023. Furthermore, it holds a prominent position in the Top 50 generics and biosimilars market for the year 2024, according to Generics Bulletin.

Glenmark is not only dedicated to business excellence but also to sustainable practices. The organization has established a noteworthy target for reducing greenhouse gas emissions, which was officially recognized by the Science Based Targets Initiative in 2023, marking it as the second pharmaceutical company in India to achieve this status. Over the last decade, their corporate social responsibility initiatives have positively impacted more than 3.3 million lives, showcasing their commitment to societal welfare.

For those interested in learning more about this newly launched product or making a purchase, further details can be found on their official website: Glenmark Pharma USA. As the market continues to evolve, Glenmark's entry signifies a promising development for consumers seeking effective over-the-counter solutions for their health needs.

Conclusion

Glenmark Therapeutics' launch of Polyethylene Glycol 3350 not only diversifies its extensive product line but also reaffirms its robust presence in the pharmaceutical market. By providing options that meet regulatory standards while addressing consumer health issues effectively, Glenmark is well-positioned to succeed in both domestic and international markets. As it moves forward, the company will likely continue to innovate and respond to the growing health needs of the global population.